Authors : N V L Suvarchala Reddy V; M. Ganga Raju; Ashritha V; Sowmika KV; Anirudh M; Avinash A; Ashritha B

Volume/Issue : Volume 9 - 2024, Issue 7 - July

Google Scholar : https://tinyurl.com/yfrz3m6v

Scribd : https://tinyurl.com/4j7m7sx8

DOI : https://doi.org/10.38124/ijisrt/IJISRT24JUL030

Abstract : Cancer is a broad category of diseases characterized through the unchecked proliferation and dissemination of atypical cells. It is among the primary causes of morbidity and mortality globally. The multistage genesis of cancer, which begins with genetic abnormalities that cause normal cells to become malignant, is what gives cancer its complexity. There are several steps involved in the genesis of cancer, including six key cancer distinguishing features known to influence malignant change has been identified. Anticancer drug development is a laborious process that includes numerous in vitro, in vivo, and clinical trials. In vitro assays provide a foundation for cancer medication development techniques. Numerous in vitro procedures and tests have been developed to analyze every defining aspect of cancer; the choice of a specific in vitro technique or assay is largely based on the research question(s) under investigation. Currently, oncology researchers are attempting to create cancer nanomedicines that are both safe and effective. While nanoparticles have opened up new therapeutic and diagnostic avenues, stem cell treatment has demonstrated potential usefulness in renewing and repairing defective or damaged tissues by tackling primary and metastatic cancer sites. With minimal harm to healthy cells, targeted therapy has the potential to stop the development and propagation of specific cancer cells. In place of open surgery, ablation therapy has become a popular minimally invasive method for destroying or freezing tumors. Naturally occurring antioxidants have demonstrated the ability to find free radicals and counteract their harmful effects, potentially treating or preventing cancer. A number of novel technologies have previously received authorization, and some are presently the subject of clinical trials. This review article's objective is to provide an extensive overview of the state of our knowledge on cancer, covering its causes, kinds, diagnosis, therapy, in vitro assays to screen cancer and most recent scientific developments.

Keywords : Cancer, In Vitro Assays, Modern Techniques, Herbal Therapy.

References :

1. Aizawa, K, Liu, C, Tang, S., Veeramachaneni, S., Hu, K. Q., Smith, D. E., & Wang, X. D. (2016). Tobacco carcinogen induces both lung cancer and non-alcoholic steatohepatitis and hepatocellular carcinomas in ferrets which can be attenuated by lycopene supplementation. International Journal of Cancer, 139(5), 1171–1181.
2. Poon, S.L., McPherson, J.R., Tan, P., Teh, B.T., Rozen, S.G. (2014) 'Mutation signatures of carcinogen exposure: genome-wide detection and new opportunities for cancer prevention', Genome Med, 6, p. 24.
3. Trafialek, J. and Kolanowski, W. (2014) 'Dietary exposure to meat-related carcinogenic substances: is there a way to estimate the risk?', Int J Food Sci Nutr, 65, pp. 774-780.
4. Cumberbatch, M.G., Cox, A., Teare, D. and Catto, J.W. (2015) 'Contemporary occupational carcinogen exposure and bladder cancer: a systematic review and meta-analysis', JAMA Oncol, 1, pp. 1282-1290.
5. Antwi, S.O., Eckert, E.C., Sabaque, C.V., et al. (2015) 'Exposure to environmental chemicals and heavy metals, and risk of pancreatic cancer', Cancer Causes Control, 26, pp. 1583-1591.
6. Parkin, D.M. (2006) 'The global health burden of infection-associated cancers in the year 2002', Int J Cancer, 118, pp. 3030-3044.
7. Seto, M., Honma, K. and Nakagawa, M. (2010) 'Diversity of genome profiles in malignant lymphoma', Cancer Sci, 101, pp. 573-578.
8. Cigudosa, J.C., Parsa, N.Z., Louie, D.C., et al. (1999) 'Cytogenetic analysis of 363 consecutively ascertained diffuse large B-cell lymphomas', Genes, Chromosomes Cancer, 25, pp. 123-133.
9. Shtivelman, E., Lifshitz, B., Gale, R.P. and Canaani, E. (1985) 'Fused transcript of abl and bcr genes in chronic myelogenous leukaemia', Nature, 315, pp. 550-554.
10. Kerr, J.F., Wyllie, A.H. and Currie, A.R. (1972) 'Apoptosis: A Basic Biological Phenomenon with Wide-ranging Implications in Tissue Kinetics', British Journal of Cancer, 26(4), pp. 239-257.
11. Gavrieli, Y., Sherman, Y. and Ben-Sasson, S.A. (1992) 'Identification of Programmed Cell Death in situ via Specific Labeling of Nuclear DNA Fragmentation', Journal of Cell Biology, 119(3), pp. 493-501.
12. Olive, P.L. and Banáth, J.P. (2006) 'The Comet Assay: A Method to Measure DNA Damage in Individual Cells', Nature Protocols, 1, pp. 23-29.
13. Decker, T. and Lohmann-Matthes, M.L. (1988) 'A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity', Journal of Immunological Methods, 115(1), pp. 61-69.
14. Korzeniewski, C. and Callewaert, D.M. (1983) 'An enzyme-release assay for natural cytotoxicity', Journal of Immunological Methods, 64(3), pp. 313-320.
15. Fotakis, G. and Timbrell, J.A. (2006) 'In vitro cytotoxicity assays: comparison of LDH, neutral red, MTT, and protein assay in hepatoma cell lines following exposure to cadmium chloride', Toxicology Letters, 160(2), pp. 171-177.
16. Rubinstein, L.V., Shoemaker, R.H., Paull, K.D., Simon, R.M., Tosini, S., Skehan, P., et al. (1990) 'Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay: proposed improvements in the screening process', Journal of the National Cancer Institute, 82(13), pp. 1114-1118.
17. Koh, W., Mow, B. and Stoltzfus, J. (2015) 'Validation of lactate dehydrogenase as a biomarker for in vitro cellular toxicity', Journal of Pharmacological and Toxicological Methods, 71, pp. 13-17.
18. Skehan, P., Storeng, R., Scudiero, D., Monks, A., McMahon, J., Vistica, D., Warren, J.T., Bokesch, H., Kenney, S. and Boyd, M.R. (1990) 'New colorimetric cytotoxicity assay for anticancer-drug screening', Journal of the National Cancer Institute, 82(13), pp. 1107-1112.
19. Vichai, V. and Kirtikara, K. (2006) 'Sulforhodamine B colorimetric assay for cytotoxicity screening', Nature Protocols, 1(3), pp. 1112-1116.
20. Keepers, Y.P., Pizao, P.E., Peters, G.J., van Ark-Otte, J., Winograd, B. and Pinedo, H.M. (1991) 'Comparison of the Sulforhodamine B protein and tetrazolium (MTT) assays for in vitro chemosensitivity testing', European Journal of Cancer, 27(7), pp. 897-900.
21. Orellana, E.A. and Kasinski, A.L. (2016) 'Sulforhodamine B (SRB) Assay in Cell Culture to Investigate Cell Proliferation', Bio-Protocol, 6(21), e1984.
22. Pauwels, B., Korst, A.E.C., de Pooter, C.M.J., Pattyn, G.G.O. and Lambrechts, H.A.J. (2003) 'Comparison of the Sulforhodamine B assay and the clonogenic assay for in vitro chemoradiation studies', Cancer Chemotherapy and Pharmacology, 51(3), pp. 221-226.
23. Ahmed, S.A., Gogal Jr, R.M. and Walsh, J.E. (1994) 'A new rapid and simple non-radioactive assay to monitor and determine the proliferation of lymphocytes: an alternative to [3H]thymidine incorporation assay', Journal of Immunological Methods, 170(2), pp. 211-224.
24. O'Brien, J., Wilson, I., Orton, T. and Pognan, F. (2000) 'Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity', European Journal of Biochemistry, 267(17), pp. 5421-5426.
25. Rampersad, S.N. (2012) 'Multiple applications of Alamar Blue as an indicator of metabolic function and cellular health in cell viability bioassays', Sensors, 12(9), pp. 12347-12360.
26. Page, B., Page, M. and Noel, C. (1993) 'A new fluorometric assay for cytotoxicity measurements in vitro', International Journal of Oncology, 3(3), pp. 473-476.
27. Hamid, R., Rotshteyn, Y., Rabadi, L., Parikh, R. and Bullock, P. (2004) 'Comparison of Alamar Blue and MTT assays for high-throughput screening', Toxicology in Vitro, 18(5), pp. 703-710.
28. Galsky, A.G. and Wilsey, J.P. (1980) 'Crown gall tumor disc bioassay: a possible aid in the detection of compounds with antitumor activity', Plant Physiology, 65(1), pp. 184-185.
29. M.F. (2006) 'A modified potato disc antitumor assay', Journal of Medicinal Plants Research, 10(2), pp. 34-39.
30. McLaughlin, J.L. (1991) 'Crown-gall tumors on potato discs and brine shrimp lethality: two simple bioassays for higher plant screening and fractionation', Methods in Plant Biochemistry, 6, pp. 1-32.
31. Boyd, M.R. and Paull, K.D. (1995) 'Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen', Drug Development Research, 34(2), pp. 91-109.
32. Gerhauser, C., Lee, S.K., Kosmeder, J.W., Moriarty, R.M., Hamel, E., Mehta, R.G., et al. (1999) 'Regulation of ornithine decarboxylase induction by deguelin, a natural product cancer chemopreventive agent', Cancer Research, 59(3), pp. 338-343.
33. Arruebo, M., Vilaboa, N., Sáez-Gutierrez, B., et al. (201
34. Assessment of the evolution of cancer treatment therapies', Cancers, 3(3), pp. 3279-3330.
35. Jaffe, N. (2008) 'The role of chemotherapy in the treatment of osteosarcoma', Advances in Experimental Medicine and Biology, 624, pp. 1-30.
36. Eng, C. (2009) 'The evolving role of monoclonal antibodies in colorectal cancer: early presumptions and impact on clinical trial development', Oncologist, 14(3), pp. 245-257.
37. Fojo, T., Mailankody, S. and Lo, A. (2014) 'Unintended consequences of expensive cancer therapeutics—the pursuit of marginal indications and a me-too mentality that stifles innovation and creativity: the John Conley Lecture', JAMA Otolaryngology–Head & Neck Surgery, 140(12), pp. 1225-1236.
38. Miller, K.D., Fidler-Benaoudia, M., Keegan, T.H., et al. (2020) 'Cancer statistics for adolescents and young adults, 2020', CA: A Cancer Journal for Clinicians, 70(6), pp. 443-459.
39. Siegel, R.L., Miller, K.D., Fuchs, H.E. and Jemal, A. (2021) 'Cancer statistics, 2021', CA: A Cancer Journal for Clinicians, 71(1), pp. 7-33.
40. Gupta, S.C., Hevia, D., Patchva, S., Park, B., Koh, W. and Aggarwal, B.B. (2012) 'Upsides and downsides of reactive oxygen species for cancer: the roles of reactive oxygen species in tumorigenesis, prevention, and therapy', Antioxidants & Redox Signaling, 16(11), pp. 1295-1322.
41. Prasad, S., Gupta, S.C. and Aggarwal, B.B. (2017) 'Serum and plasma biomarkers in cancer diagnosis and prognosis', Antioxidants & Redox Signaling, 26(17), pp. 1516-1556.
42. Gage, A.A. and Baust, J. (1998) 'Mechanisms of tissue injury in cryosurgery', Cryobiology, 37(3), pp. 171-186.
43. Korpan, N.N. (2007) 'A history of cryosurgery: its development and future', Journal of the American College of Surgeons, 204(2), pp. 314-324.
44. Radiological Society of North America (RSNA) and American College of Radiology (ACR) (2020) 'Radiofrequency ablation (RFA) / microwave ablation (MWA) of liver tumors' [Internet]. Oak Brook, IL: Radiological Society of North America; Reston, VA: American College of Radiology.
45. Brace, C. (2011) 'Thermal tumor ablation in clinical use', IEEE Pulse, 2(5), pp. 28-38.
46. Ingram, D., Sanders, K., Kolybaba, M. and Lopez, D. (1997) 'Case-control study of phyto-oestrogens and breast cancer', The Lancet, 350(9083), pp. 990-994.
47. Messina, M.J. (1999) 'Legumes and soybeans: overview of their nutritional profiles and health effects', The American Journal of Clinical Nutrition, 70(3), supplement, pp. 439S-450S.
48. Yamamoto, S., Sobue, T., Kobayashi, M., et al. (2003) 'Soy, isoflavones, and breast cancer risk in Japan', Journal of the National Cancer Institute, 95(12), pp. 906-913.
49. American Cancer Society (ACS) (2009) 'Breast cancer facts and figures'.
50. American Cancer Society (ACS) (2013) 'What are the key statistics about lung cancer?'.
51. Franek, K.J., Zhou, Z., Zhang, W.D. and Chen, W.Y. (2005) 'In vitro studies of baicalin alone or in combination with Salvia miltiorrhiza extract as a potential anti-cancer agent', International Journal of Oncology, 26(1), pp. 217-224.
52. Jonat, W., Pritchard, K.I., Sainsbury, R. and Klijn, J.G. (2006) 'Trends in endocrine therapy and chemotherapy for early breast cancer: a focus on the premenopausal patient', Journal of Cancer Research and Clinical Oncology, 132(5), pp. 275-286.
53. Di, G.H., Li, H.C., Shen, Z.Z. and Shao, Z.M. (2003) 'Analysis of anti-proliferation of curcumin on human breast cancer cells and its mechanism', Zhonghua Yi Xue Za Zhi, 83(20), pp. 1764-1768.
54. Wu, C., Chen, F., Rushing, J.W., et al. (2006) 'Antiproliferative activities of parthenolide and golden feverfew extract against three human cancer cell lines', Journal of Medicinal Food, 9(1), pp. 55-61.
55. Zhang, W., Li, Y., Zhang, G., Lü, J. and Ou, H. (2005) 'Experimental study on MCF-7 cell apoptosis induced by ursolic acid', Zhong Yao Cai, 28(4), pp. 297-301.
56. Kuo, P.L., Hsu, Y.L. and Cho, C.Y. (2006) 'Plumbagin induces G2-M arrest and autophagy by inhibiting the AKT/mammalian target of rapamycin pathway in breast cancer cells', Molecular Cancer Therapeutics, 5(12), pp. 3209-3221.
57. Sundar, S.N., Marconett, C.N., Doan, V.B., Willoughby, J.A., Sr., and Firestone, G.L. (2008) 'Artemisinin selectively decreases functional levels of estrogen receptor-α and ablates estrogen-induced proliferation in human breast cancer cells', Carcinogenesis, 29(12), pp. 2252-2258.
58. Miocinovic, R., McCabe, N.P., Keck, R.W., Jankun, J., Hampton, J.A. and Selman, S.H. (2005) 'In vivo and in vitro effect of baicalein on human prostate cancer cells', International Journal of Oncology, 26(1), pp. 241-246.
59. Pidgeon, G.P., Kandouz, M., Meram, A. and Honn, K.V. (2002) 'Mechanisms controlling cell cycle arrest and induction of apoptosis after 12-lipoxygenase inhibition in prostate cancer cells', Cancer Research, 62(9), pp. 2721-2727.
60. Tsai, C.H., Lin, F.M., Yang, Y.C., et al. (2009) 'Herbal extract of Wedelia chinensis attenuates androgen receptor activity and orthotopic growth of prostate cancer in nude mice', Clinical Cancer Research, 15(17), pp. 5435-5444.
61. Nelson, P.S. and Montgomery, B. (2003) 'Unconventional therapy for prostate cancer: good, bad or questionable?', Nature Reviews Cancer, 3(11), pp. 845-858.